Context Therapeutics Inc. (NASDAQ:CNTX) Receives Average Recommendation of "Moderate Buy" from Brokerages

Key Points

• Context Therapeutics Inc. has been given an average rating of "Moderate Buy" from nine brokerages, with price targets ranging from $4.00 to $9.00.
• The company reported a missed earnings expectation of ($0.09) EPS, falling short of the consensus estimate of ($0.06).
• Institutional investors own 14.03% of Context Therapeutics' stock, with Millennium Management LLC increasing its stake by 24.2% in the last quarter.

Context Therapeutics Inc. (NASDAQ:CNTX - Get Free Report) has been given an average rating of "Moderate Buy" by the nine brokerages that are covering the stock, Marketbeat reports. One research analyst has rated the stock with a sell recommendation, seven have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average 1-year price target among analysts that have issued ratings on the stock in the last year is $5.20.

A number of brokerages have issued reports on CNTX. D. Boral Capital reiterated a "buy" rating and set a $9.00 price target on shares of Context Therapeutics in a research report on Thursday, August 7th. Cantor Fitzgerald began coverage on Context Therapeutics in a research report on Thursday. They set an "overweight" rating for the company. Piper Sandler reiterated an "overweight" rating and set a $4.00 price target (down previously from $4.50) on shares of Context Therapeutics in a research report on Thursday, June 26th. HC Wainwright reduced their price target on Context Therapeutics from $5.00 to $4.00 and set a "buy" rating for the company in a research report on Thursday, August 7th. Finally, Weiss Ratings reiterated a "sell (d-)" rating on shares of Context Therapeutics in a research report on Saturday, September 27th.

Institutional Trading of Context Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Millennium Management LLC raised its stake in shares of Context Therapeutics by 24.2% in the 4th quarter. Millennium Management LLC now owns 178,718 shares of the company's stock worth $188,000 after buying an additional 34,835 shares in the last quarter. Citadel Advisors LLC bought a new stake in shares of Context Therapeutics in the 4th quarter worth $31,000. Finally, Jane Street Group LLC bought a new stake in shares of Context Therapeutics in the 4th quarter worth $29,000. Institutional investors own 14.03% of the company's stock.

Context Therapeutics Price Performance

NASDAQ:CNTX opened at $1.10 on Friday. Context Therapeutics has a 12-month low of $0.49 and a 12-month high of $2.59. The firm has a market capitalization of $98.67 million, a P/E ratio of -3.06 and a beta of 1.93. The business has a 50 day simple moving average of $0.85 and a 200 day simple moving average of $0.77.

Context Therapeutics (NASDAQ:CNTX - Get Free Report) last released its quarterly earnings data on Wednesday, August 6th. The company reported ($0.09) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.06) by ($0.03). Research analysts anticipate that Context Therapeutics will post -0.51 EPS for the current fiscal year.

About Context Therapeutics

Context Therapeutics Inc, a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.